Summary
Major players in the plasma protein therapeutics market are Octapharma AG, CSL Behring LLC, Grifols S.A, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion S.p.A., Shire PLC., LFB GROUP, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions B.V., Bio Products Laboratory Ltd., and MP Biomedicals LLC.
The global plasma protein therapeutics market is expected to grow from $26.25 billion in 2022 to $28.11 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The plasma protein therapeutics market is expected to reach $35.84 billion in 2027 at a CAGR of 6.3%.
The plasma protein therapeutics market includes revenues earned by entities by providing therapy for liver disease and bleeding from trauma by using Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins.The market value includes the value of related goods sold by the service provider or included within the service offering.
Only goods and services traded between entities or sold to end consumers are included.
Plasma protein therapeutics refers to therapies derived from plasma and their recombinant analogs. It is used for the treatment of specific medical conditions by replacing missing or deficient proteins found in plasma, allowing recipients to live healthier and more productive lives.
North America was the largest region in the plasma protein therapeutics market in 2022.Asia-Pacific is expected to be the fastest-growing region in the forecast period.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main products of plasma protein therapeutics are immunoglobulin, albumin, coagulation factor, c1-esterase inhibitors, and other products.Immunoglobulin refers to a component of blood plasma that contains immunoglobulins or antibodies.
These are administrated through different routes of administration including intravenous, and subcutaneous and are used for various applications such as primary immunodeficiency disorder (PID), idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema and other applications.
An increasing prevalence of autoimmune disorders is expected to propel the growth of the plasma protein therapeutics market going forward.An autoimmune disorder is a condition that emerges when the body’s immune system attacks and destroys healthy body cells.
Therapeutic plasma exchange is used to treat autoimmune diseases, which emerge when the body misidentifies a part of itself as foreign and produces proteins (known as autoantibodies) that attack the part of the body that is misidentified.For instance, in September 2021, according to Scientific American, a US-based science magazine, autoimmune diseases affect about 4% of the global population.
Furthermore, in May 2020, according to the National Library of Medicine, a US-based biomedical library, autoimmunity diseases have a 2 to 1 prevalence rate for women. Therefore, the increasing prevalence of autoimmune disorders is driving the growth of the plasma protein therapeutics market going forward.
Product innovations are a key trend gaining popularity in the plasma protein therapeutic gaining market.Major companies operating in the plasma protein therapeutic sector are focused on innovative products to gain a competitive advantage in the market.
For instance, November 2021, Biognosys a Switzerland-based biotechnology company launched an innovative next-Generation blood biomarker discovery solution.The service is intended to assist researchers in deciphering the complexities of the blood proteome and unlocking unbiased discoveries for pharmaceutical and diagnostic development, as well as precision medicine.
A unique feature of both solutions is Biognosys’ Hyper Reaction Monitoring (HRMTM) technology and its optimized Liquid Chromatography-Mass Spectrometry (LC-MS) workflow.
In April 2022, Grifols S.A, a Spain-based pharmaceutical, and chemical manufacturer acquired Tiancheng (Germany) Pharmaceutical Holdings AG for € 1.6 billion ($1.72 billion). This acquisition is expected to accelerate and expand Grifols’ product portfolio, increase patient access to plasma therapies, and drive revenue growth and margin expansion. Biotest is a Germany-based healthcare company specializing in innovative hematology and clinical immunology and focused on developing, manufacturing, and marketing plasma proteins and biotherapeutic drugs.
The countries covered in the plasma protein therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The plasma protein therapeutics market research report is one of a series of new reports that provides plasma protein therapeutics market statistics, including plasma protein therapeutics industry global market size, regional shares, competitors with a plasma protein therapeutics market share, detailed plasma protein therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the plasma protein therapeutics industry. This plasma protein therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
